During the corresponding time, Roivant Sciences Ltd saw a revenue deteriorated by -33.55 % year on year, sequentially revenue fell by -42.78 %. While revenue at the Roivant Sciences Ltd 's corporate clients
In a significant development for the management of uncontrolled Graves disease (GD), Immunovant, Inc. has released pivotal data concerning its investigational therapy, batoclimab. The findings, which will be formally presented at the upcoming Annual Meeting of the American Thyroid Association (ATA) on September 11, 2025, indicate that patients treated with batoclimab experienced a six-month, treatment-free remission following a 24-week course of therapy. Graves disease, an autoimmune disorder that leads to hyperthyroidism, can significantly affect patients quality of life and may necessitate ongoing treatment to manage symptoms. Current therapeutic options are often limited, exposing the need for innovati...
The field of immunology continues to evolve with promising advancements in therapeutic options for autoimmune diseases. A noteworthy development is the emergence of batoclimab, an investigational fully human IgG1 monoclonal antibody targeting the neonatal Fc receptor (FcRn). This innovative therapeutic has recently shown positive results across multiple autoimmune conditions, including myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), and Graves disease (GD). This article summarizes key findings from recent clinical trials, providing insight into batoclimab s potential as a transformative treatment. Positive Results in Myasthenia Gravis On March 19, 2025, Immunovant, Inc...
Immunovant, a clinical-stage immunology company, has reported highly encouraging results from the initial cohort of patients in a 24-week Phase 2 clinical trial for batoclimab, a potential breakthrough therapy for Graves disease. The results of this trial have surpassed expectations, with response rates exceeding 50%. This achievement represents a significant advancement in the treatment of Graves disease, highlighting the potential for batoclimab to enable normal lives for individuals living with this autoimmune disorder.Enhancing Lives through Advanced Immunology:Immunovant, Inc. (Nasdaq: IMVT) remains steadfast in its mission to revolutionize the lives of people suffering from autoimmune diseases. Graves ...
Roivant s IMVT-1402 Demonstrates Best-in-Class Potential in Phase 1 Clinical Trial, Potentially Revolutionizing Treatment for Autoimmune Diseases Immunovant, Inc. (Nasdaq: IMVT), a leading clinical-stage immunology company dedicated to revolutionizing treatment options for autoimmune diseases, has recently released positive initial results from a Phase 1 clinical trial of IMVT-1402. The data was obtained from a cohort of healthy adults who received four subcutaneously administered doses of 600 mg. The results of the trial are groundbreaking, confirming IMVT-1402 s potential as a best-in-class neonatal fragment crystallizable receptor (FcRn) inhibitor. The drug demonstrated a mean IgG reduction compar...
Sources:
Roivant Sciences Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Roivant Sciences Ltd’s corporate clients.
For your research, we’ve provided 9 tables on Roivant Sciences Ltd corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
100 %